BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25758338)

  • 21. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.
    Selleri C; Montuori N; Ricci P; Visconte V; Carriero MV; Sidenius N; Serio B; Blasi F; Rotoli B; Rossi G; Ragno P
    Blood; 2005 Mar; 105(5):2198-205. PubMed ID: 15494432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4.
    Kiyan Y; Tkachuk S; Hilfiker-Kleiner D; Haller H; Fuhrman B; Dumler I
    J Mol Cell Cardiol; 2014 Jan; 66():72-82. PubMed ID: 24239845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential regulation of ERK1/2 and p38(MAPK) by components of the Rho signaling pathway during sphingosine-1-phosphate-induced smooth muscle cell migration.
    Galaria II; Fegley AJ; Nicholl SM; Roztocil E; Davies MG
    J Surg Res; 2004 Dec; 122(2):173-9. PubMed ID: 15555614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway.
    Kiian I; Tkachuk N; Haller H; Dumler I
    Thromb Haemost; 2003 May; 89(5):904-14. PubMed ID: 12719789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor.
    Kiyan J; Kusch A; Tkachuk S; Krämer J; Haller H; Dietz R; Smith G; Dumler I
    Atherosclerosis; 2007 Dec; 195(2):254-61. PubMed ID: 17275828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells.
    Dumler I; Weis A; Mayboroda OA; Maasch C; Jerke U; Haller H; Gulba DC
    J Biol Chem; 1998 Jan; 273(1):315-21. PubMed ID: 9417082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).
    Pliyev BK
    Mol Cell Biochem; 2009 Jan; 321(1-2):111-22. PubMed ID: 18830568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
    Jo M; Thomas KS; Wu L; Gonias SL
    J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
    Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
    Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
    Kiyan Y; Limbourg A; Kiyan R; Tkachuk S; Limbourg FP; Ovsianikov A; Chichkov BN; Haller H; Dumler I
    Arterioscler Thromb Vasc Biol; 2012 Jan; 32(1):110-22. PubMed ID: 22075245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.
    Resnati M; Pallavicini I; Wang JM; Oppenheim J; Serhan CN; Romano M; Blasi F
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1359-64. PubMed ID: 11818541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanisms of Participation of the Urokinase Receptor in Directed Axonal Growth].
    Klimovich PS; Semina EV
    Mol Biol (Mosk); 2020; 54(1):103-113. PubMed ID: 32163394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
    Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
    Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production.
    Lee GL; Chang YW; Wu JY; Wu ML; Wu KK; Yet SF; Kuo CC
    Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2751-60. PubMed ID: 22995520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
    Smith PC; Santibañez JF; Morales JP; Martinez J
    J Periodontal Res; 2004 Dec; 39(6):380-7. PubMed ID: 15491342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
    Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
    Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.